Evidence map›Paper›PMID 39269833›Full record

ArticleJournal of Alzheimer's disease : JAD2024

Molecular Gene Expression Testing to Identify Alzheimer's Disease with High Accuracy from Fingerstick Blood.

Bruce Seligmann, Salvatore Camiolo, Monica Hernandez, Joanne M Yeakley, Gregory Sahagian, Joel McComb

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bruce SeligmannBioSpyder Technologies, Inc., Carlsbad, CA, USA.
Salvatore CamioloBioSpyder Technologies, Inc., Carlsbad, CA, USA.
Monica HernandezBioSpyder Technologies, Inc., Carlsbad, CA, USA.
Joanne M YeakleyBioSpyder Technologies, Inc., Carlsbad, CA, USA.
Gregory SahagianNeurology Center of Southern California, Carlsbad, CA, USA.
Joel McCombBioSpyder Technologies, Inc., Carlsbad, CA, USA.

Funding

Whole blood filter paper assay for Alzheimers DiseaseR44AG065039 · NIA · BIOSPYDER TECHNOLOGIES, INC. · PI SELIGMANN, BRUCE E. · 2023 to 2024
$2.6M
NIA NIH HHS R44 AG065039
6 · The paper itself

Abstract

Background: There is no molecular test for Alzheimer's disease (AD) using self-collected samples, nor is there a definitive molecular test for AD. We demonstrate an accurate and potentially definitive TempO-Seq® gene expression test for AD using fingerstick blood spotted and dried on filter paper, a sample that can be collected in any doctor's office or can be self-collected. Objective: Demonstrate the feasibility of developing an accurate test for the classification of persons with AD from a minimally invasive sample of fingerstick blood spotted on filter paper which can be obtained in any doctor's office or self-collected to address health disparities. Methods: Fingerstick blood samples from patients clinically diagnosed with AD, Parkinson's disease (PD), or asymptomatic controls were spotted onto filter paper in the doctor's office, dried, and shipped to BioSpyder for testing. Three independent patient cohorts were used for training/retraining and testing/retesting AD and PD classification algorithms. Results: After initially identifying a 770 gene classification signature, a minimum set of 68 genes was identified providing classification test areas under the ROC curve of 0.9 for classifying patients as having AD, and 0.94 for classifying patients as having PD. Conclusions: These data demonstrate the potential to develop a screening and/or definitive, minimally invasive, molecular diagnostic test for AD and PD using dried fingerstick blood spot samples that are collected in a doctor's office or clinic, or self-collected, and thus, can address health disparities. Whether the test can classify patients with AD earlier then possible with cognitive testing remains to be determined.

Indexed as

Alzheimer DiseaseAgedAged, 80 and overBlood Specimen CollectionFemaleGene Expression ProfilingHumansMaleMiddle AgedParkinson DiseaseAlzheimer’s diseasedementiadiagnostic classifierfingerstick bloodgene expression signaturehealth disparityParkinson’s diseaseself-testTempO-Seqwhole blood

Identifiers

PMID39269833
PMCPMC11492108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.